Beneficial Ownership Report · SCHEDULE 13G
Veradermics, Incorporated
MANENYSEEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G
primary_doc.xml
Subject company
- Company
- Veradermics, Inc
- Company CIK
- 0001827635
- Street
- 470 James St.
- City
- New Haven
- State / country code
- CT
- Postal code
- 06513
Statement details
- Security class
- Common stock, par value $0.00001 per share
- Event date
- 09/30/2026
- Rule designation
- Rule 13d-1(b)
Reporting person 1
- Name
- JPMORGAN CHASE & CO.
- Citizenship / organization
- DE
- Reporting person type
- HC
- Aggregate amount owned
- 2,374,502.0
- Percent of class
- 5.6
- Sole voting power
- 2,231,159.0
- Shared voting power
- 1.0
- Sole dispositive power
- 2,374,185.0
- Shared dispositive power
- 1.0
Item 1
Issuer
Veradermics, Inc
Principal executive office address
470 James St. New Haven CT 06513
Item 2
Citizenship
DE
Filing person
JPMORGAN CHASE & CO.
Principal business or residence address
270 Park Avenue,,New York, NY 10017
Item 3
Not applicable indication
N
Type of filing person
HC
Item 4
Percent of class
5.6
Amount beneficially owned
2374502
Sole voting power
2231159
Shared voting power
1
Sole dispositive power
2374185
Shared dispositive power
1
Item 5
Not applicable indication
Y
Ownership of 5% or less
N
Item 6
Not applicable indication
N
Ownership on behalf of another person
Not Applicable
Item 7
Not applicable indication
N
Subsidiaries
J.P. Morgan Securities LLC; JPMorgan Asset Management (UK) Limited; JPMorgan Chase Bank, National Association; J.P. Morgan Investment Management Inc.; J.P. Morgan Wealth Management Solutions Inc.
Item 8
Not applicable indication
N
Group members
Not Applicable
Item 9
Not applicable indication
N
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Signature 1
- Reporting person
- JPMORGAN CHASE & CO.
- Signed
- Rachel Tsvaygoft
- Title
- Vice President
- Date
- 10/13/2026
Company context
We are a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Our initial focus is developing better treatments for pattern hair loss, or PHL, a condition affecting approximately 50 million men and 30 million women in the United States. Current PHL treatment options are limited and therefore are consistently plagued with high rates of treatment failure, patient dissatisfaction and treatment discontinuation. Patients and healthcare providers routinely identify the following shortcomings with currently available treatment options: